跳至主要内容
临床试验/DRKS00026775
DRKS00026775招募中2 期

Randomized controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients - MinT

niversität Heidelberg0 个研究点目标入组 60 人开始时间: 2022年7月7日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patient in a palliative stage of disease.
  • -Age = 18 years
  • -Personal information of the patient by one of the investigators.
  • -Ability of the participant to understand the nature and scope of the clinical trial
  • -Written informed consent of the patient
  • -Diagnosis final phase
  • -Diagnosis of terminal agitation
  • -RASS-PAL Score > 0

排除标准

  • -Diseases affecting nasal absorption.
  • -Hypersensitivity to midazolam or to any other component/excipient of the study medication
  • -Parallel use of strong CYP 3A4 inducers or CYP 3A4 inhibitors
  • -Other causes are responsible for the observed agitation symptomatology and can be treated causally
  • -A non-drug therapy is effective and leads to improvement of the restlessness symptoms
  • -Pregnant and breastfeeding women

研究者

发起方
niversität Heidelberg

相似试验